Cytokine Signalling Forum

Publications





January 20

L'upadacitinib améliore les résultats déclarés par les patients chez des patients atteints de polyarthrite rhumatoïde et une réponse inadéquate aux médicaments antirhumatismaux modificateurs de la maladie de synthèse conventionnels: résultats de SELECT-NEXT

Strand V, Pope J, Tundia N, Friedman A, Camp H, Pangan A, Ganguli A, Fuldeore M, Goldschmidt D, Schiff M.
Arthritis Res Ther . 2019 Dec 9;21(1):272.

In SELECT-NEXT, UPA demonstrated clinically meaningful improvements in patient reported outcomes compared to PBO in patients with RA who had an inadequate response to csDMARDs. In this post hoc analysis, the effect of UPA 15 or 30 mg on patient reported outcomes were assessed and compared to PBO. Eligible patients (661) with an inadequate response to csDMARDs were randomly assigned 2:2:1:1 to receive background csDMARD therapy with either UPA 15 mg, UPA 30 mg or PBO. PROs collected at Wk4 and Wk...

Mots clefs: JAK, Upadacitinib, Clinical, PRO

Traduit par: Héléna Farese